Join
Live feed
·
PRReleasevia Quantisnow
AbCellera Biologics Inc. logo

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

ByQuantisnow·Wall Street's wire, on your screen.
ABCL· AbCellera Biologics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ABCL (AbCellera Biologics Inc.) and more on Quantisnow.